Zobrazeno 1 - 10
of 21
pro vyhledávání: ''
Autor:
Eiji Shinozaki, Hiroki Osumi, Mariko Ogura, Keisho Chin, Kensei Yamaguchi, Izuma Nakayama, Daisaku Kamiimabeppu, Takeru Wakatsuki, Keitaro Shimozaki, Daisuke Takahari, Akira Ooki
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8820-8828 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8820-8828 (2021)
Background Circulating tumor DNA (ctDNA) is a biomarker with potential to reflect comprehensive genomic information and overcome intratumor heterogeneity. In contrast, carcinoembryonic antigen (CEA) is a conventional tumor marker for predicting recur
Autor:
Todd C. Knepper, Robyn A Panchaud, Nikhil I. Khushalani, Elnara Muradova, Andrew S. Brohl, Leah Cohen, Kenneth Y. Tsai, James A. DeCaprio
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 17, Pp 5889-5896 (2021)
Cancer Medicine, Vol 10, Iss 17, Pp 5889-5896 (2021)
Background The use of targeted therapy remains a treatment consideration for some patients with advanced Merkel cell carcinoma (MCC). However, supportive data on the use of targeted therapy approaches are limited. Thus, we sought to evaluate the resp
Autor:
Shiyue Zhang, Youming Lei, Juan Zhao, Songhui Zhao, Wen-Jing Wang, Ming Yao, Xiaowei Dong, Kai Wang, Li Liu, Qing Zhou, Yunfei Shi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 7, Pp 2216-2231 (2021)
Cancer Medicine, Vol 10, Iss 7, Pp 2216-2231 (2021)
Objectives This study aimed to explore the novel biomarkers for immune checkpoint inhibitor (ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling, tumor mutational burden (TMB), and expression of programmed death re
Autor:
Shigenori Kadowaki, Michi Sawabe, Michihiko Sone, Hoshino Terada, Hidenori Suzuki, Nobuhiro Hanai, Daisuke Nishikawa, Shintaro Beppu
Publikováno v:
Cancer Science
Although nivolumab, a programmed cell death 1 (PD‐1) inhibitor, is a standard therapy for platinum‐refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), no definitive biomarkers have been reported thus far. This st
Autor:
Linzhi Han, Yan Gong, Hongjie Shi, Conghua Xie, Xueping Jiang, Nannan Zhang, Yuan Luo, Shuying Li, Wenjie Sun
Publikováno v:
Cancer Medicine
Lung adenocarcinoma (LUAD) is the most common and lethal cancer worldwide. Radiotherapy (RT) is widely used at all stages of LUAD, and the development of immunotherapy substantially enhances the survival of LUAD patients. Although the emerging treatm
Autor:
Qian Zhan, Dan Chen, Shi Chen, Baiyong Shen, Xiaxing Deng, Wenjing Qi, Jiabin Jin, Jun Zhang, Xue Song, Dandan Ren, Zhiwei Xu, Chenghong Peng, Junjie Xie, Jiangning Gu, Chenlei Wen, Jiancheng Wang, Dongfeng Cheng, Hao Chen
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 20, Pp 7626-7636 (2020)
Cancer Medicine, Vol 9, Iss 20, Pp 7626-7636 (2020)
Objective Our study examined the association between molecular features and clinical results of pancreatic ductal adenocarcinoma (PDAC) patients, aiming to explore the genomic determinants of the recurrence and prognosis of PDAC after surgical remova
Autor:
Renquan Lu, Lin Guo, Hui Zheng, Shuang Ma, Jinyan Kai, Suhong Xie, Meiqin Zhang, Yanchun Wang, Qian Ma, Yixuan Liu, Wenting Yang
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 14, Pp 5200-5209 (2020)
Cancer Medicine, Vol 9, Iss 14, Pp 5200-5209 (2020)
Background Ovarian cancer (OC) is the deadliest gynecological cancer. The absence of biomarkers in early detection and chemotherapy resistance is a principal cause of treatment failure in OC. Methods In this study, next generation sequencing (NGS) wa
Autor:
Shan Xing, Lin Chen, Wanli Liu, Sheng Qin, Jianhua Xu, Xianzhang Huang, Yonghe Chen, Kai Lan, Wan Wang, Rongliang Liang, Caiying Bai, Haibiao Lin, Fudong Luo, Dan Liu
Publikováno v:
Cancer Science
The signaling of interleukin (IL)‐23 and its receptor (IL‐23R) play a crucial role in the development of cancers. However, the clinical significance of human serum soluble IL‐23R (sIL‐23R) and its relationship with IL‐23 are still not explo
Publikováno v:
Cancer Science
The identification of useful biomarkers is an urgent issue in cancer treatment, particularly for immunotherapy, as only some patients experience benefits from this treatment. The early induction of the IgG response has been reported as a useful bioma
Autor:
Thomas Urup, Helle Broholm, Hans Skovgaard Poulsen, Linn Gillberg, Vibeke Andrée Larsen, Katja Kaastrup, Ib Jarle Christensen, Ulrik Lassen, Maya Jeje Schuang Lü, Kirsten Grønbæk, Signe Regner Michaelsen
Publikováno v:
Molecular Oncology
Urup, T, Gillberg, L, Kaastrup, K, Lü, M J S, Michaelsen, S R, Andrée Larsen, V, Christensen, I J, Broholm, H, Lassen, U, Grønbæk, K & Poulsen, H S 2020, ' Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma ', Molecular Oncology, vol. 14, no. 5, pp. 964-973 . https://doi.org/10.1002/1878-0261.12660
Molecular Oncology, Vol 14, Iss 5, Pp 964-973 (2020)
Urup, T, Gillberg, L, Kaastrup, K, Lü, M J S, Michaelsen, S R, Andrée Larsen, V, Christensen, I J, Broholm, H, Lassen, U, Grønbæk, K & Poulsen, H S 2020, ' Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma ', Molecular Oncology, vol. 14, no. 5, pp. 964-973 . https://doi.org/10.1002/1878-0261.12660
Molecular Oncology, Vol 14, Iss 5, Pp 964-973 (2020)
Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because